A5046764038- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Melanoma and MAPK Pathways
- Genetic factors in colorectal cancer
- Neuroendocrine Tumor Research Advances
- CAR-T cell therapy research
- Cellular Mechanics and Interactions
- Immunotherapy and Immune Responses
- Tissue Engineering and Regenerative Medicine
- Cancer Research and Treatments
- Pancreatic function and diabetes
- TGF-β signaling in diseases
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Lung Cancer Treatments and Mutations
- Renal cell carcinoma treatment
- Caveolin-1 and cellular processes
- Phagocytosis and Immune Regulation
- Nanoplatforms for cancer theranostics
- Ferroptosis and cancer prognosis
- Colorectal and Anal Carcinomas
- Cancer, Hypoxia, and Metabolism
- ATP Synthase and ATPases Research
- Lymphoma Diagnosis and Treatment
University of California, San Diego
2021-2025
Moores Cancer Center
2021-2023
Scripps MD Anderson Cancer Center
2018-2022
Scripps Research Institute
2022
UC San Diego Health System
2021-2022
La Jolla Alcohol Research
2022
Discovery Institute
2018-2021
Sanford Burnham Prebys Medical Discovery Institute
2019-2021
Center for Personalized Cancer Treatment
2021
Cancer Research Center
2021
Circulating tumor DNA (ctDNA) analyses allow for postoperative risk stratification in patients with curatively treated colon and breast cancers. Use of ctDNA esophagogastric cancers (EGC) is less characterized could identify high-risk who have been curative intent.In this retrospective analysis real-world data, levels were analyzed the preoperative, postoperative, surveillance settings EGC using a personalized multiplex polymerase chain reaction-based next-generation sequencing assay. Plasma...
Despite progress, 2-year pancreatic cancer survival remains dismal. We evaluated a biomarker-driven, combination/N-of-one strategy in 18 patients (advanced/metastatic cancer) (from Molecular Tumor Board). Targeted agents administered/patient = 2.5 (median) (range, 1-4); first-line therapy (N 5); second line, 13). Comparing (high versus low degrees of matching) (matching score ≥50% <50%; reflecting number alterations matched to targeted divided by pathogenic alterations), was significantly...
Treatment of hematologic malignancies with patient-derived anti-CD19 chimeric antigen receptor (CAR) T-cells has demonstrated long-term remissions for patients otherwise treatment-refractory advanced leukemia and lymphoma. Conversely, CAR T-cell treatment solid tumors, including gastric cancer (GC), proven more challenging due to on-target off-tumor toxicities, poor tumor infiltration, inefficient expansion, immunosuppressive microenvironments, demanding preconditioning regimens. We report...
Abstract Pancreatic ductal adenocarcinoma (PDAC) is characterized by marked desmoplasia and drug resistance due, in part, to poor delivery extravascular tumor tissue. Here, we report that carcinoma-associated fibroblasts (CAFs) induce β5 integrin expression cells a TGF-β dependent manner, making them an efficient target for the tumor-penetrating peptide iRGD. The capacity of iRGD deliver conjugated co-injected payloads markedly suppressed when integrins are knocked out cells. Of note,...
BACKGROUND. Immune checkpoint inhibitors (ICIs) fail to demonstrate efficacy in pancreatic cancer. Recently, genomic biomarkers have been associated with response ICIs: microsatellite instability high (MSI-H) and tumor mutation burden (TMB) > 10 mutations/Mb. Alterations Switch/Sucrose Nonfermentable (SWI/SNF) chromatin remodeling genes may predispose improved outcomes immunotherapy. The current study examined a possible role for SWI/SNF complex abnormalities cancer responsiveness ICIs.
Abstract Introduction Personalized and tumor-informed circulating tumor DNA (ctDNA) testing is feasible allows for molecular residual disease (MRD) identification in patients with pancreatic ductal adenocarcinoma (PDAC). Methods In this retrospective analysis of commercial cases from multiple US institutions, personalized, tumor-informed, whole-exome sequenced, germline-controlled ctDNA levels were quantified analyzed PDAC. Plasma samples (n = 1329) 298 clinically validated collected at...
5 Background: A growing body of evidence supports the utility circulating tumor DNA (ctDNA) as a useful biomarker for detecting molecular residual disease (MRD) in colorectal cancer (CRC). Immediately after surgery or during adjuvant therapy, high levels cell-free (cfDNA) from normal tissue may limit detection tumor-derived ctDNA. The optimal timing blood collection reliable MRD therapy remains unclear. Methods: In this retrospective, U.S.-based, multi-institutional study, data commercial...
356 Background: Autologous anti-claudin 18.2 (CLDN18.2) CAR T cell, satricabtagene autoleucel (satri-cel), was developed to treat solid tumors. We report the completed results of Phase 1b ELIMYN18.2 study (Cohort A) in gastric/gastroesophageal junction (GC/GEJ) and pancreatic cancer (PC). Methods: This single-arm, open-label, 1b/2 (NCT04404595) evaluated safety efficacy satri-cel patients with CLDN18.2-positive advanced GC/GEJ or PC. Cohort A consisted a modified 3+3 design. After...
828 Background: Claudin18.2 (CLDN18.2) is a tight junction protein found in gastric epithelial cells. It can become abnormally expressed cancer and other solid tumors, rendering it candidate for targeted therapy. There are no approved therapeutic agents against CLDN18.2. The T cell antigen coupler (TAC) technology modifies cells ex vivo , allowing cytotoxicity of tumor by co-opting the natural receptor. TAC demonstrate safer profile than chimeric receptor TAC01-CLDN18.2 an autologous T-cell...
PURPOSE Circulating tumor DNA (ctDNA) is an emerging tool in the evaluation of GI cancers. Challenges remain defining its utility and role as a primary end point therapeutic trials. The National Cancer Institute (NCI) ctDNA working group was created to evaluate current data provide guidance on inclusion cancer METHODS NCI steering committee assigned four task force members serve co-chairs for group. Co-chairs identified experts within each disease form panel that convened review...
2538 Background: Claudin 18.2 (CLDN18.2) is a highly selective cell lineage marker with limited expression in normal gastric tissues and significantly higher primary gastric, pancreatic tumors their metastases. Anti-CLDN18.2-targeted CAR T cells, termed CT041, were developed to evaluate tumor response patient-reported outcomes the cancer. Preliminary results of trial (NCT03874897) showed an objective rate (ORR) about 60% cancer from non-Western population. Here we report CT041 for metastatic...
Pancreatic ductal adenocarcinomas (PDAC) are highly invasive and metastatic neoplasms commonly unresponsive to current drug therapy. Overwhelmingly, PDAC harbors early constitutive, oncogenic mutations in K-Ras(G12D) that exist prior invasion. Histologic genetic analyses of human biopsies also exhibit increased expression extracellular signal-regulated kinase (ERK) 1/2 proinvasive matrix metalloproteinases (MMP), indicators poor prognosis. However, the distinct molecular mechanisms necessary...
Pancreatic ductal adenocarcinoma (PDAC) commonly contains a mutation in K-RasG12D and is characterized by desmoplastic reaction composed of deregulated, proliferating cells embedded an abnormal extracellular matrix (ECM). Our previous observations imply that inhibiting the mitogen-activated protein kinase (MAPK)-extracellular signal-regulated (ERK2) signal pathway reverses metalloproteinase 1-specific invasive phenotype. Here, we investigated specific genes downstream MAPK-ERK2 responsible...
As with other genitourinary malignancies, a variety of paraneoplastic syndromes have been revealed to occur in patients prostate cancer. Stauffer's Syndrome is well‑described clinical syndrome which manifests via intrahepatic cholestasis renal cell carcinoma. Less common occurring association The current case report discusses 67‑year‑old man presenting liver failure secondary co‑existing metastatic adenocarcinoma. patient's completely resolved androgen‑deprivation therapy suggesting an...
Despite remarkable responses to immune checkpoint blockade (ICB) in some advanced cancers, most patients do not benefit, perhaps due the complexity of tumor/immune/genome interactions. We implemented a multidisciplinary Molecular Tumor Board (MTB) that reviewed multi-omic cancer characteristics develop N-of-One therapies for pan-cancer, advanced, refractory setting. This study evaluates experience 80 who were presented MTB and received treatment regimen included ICB. Overall, 60/80 (75%) ICB...
Anal squamous cell carcinoma (SCCA) is an uncommon malignancy with a rising incidence that has high cure rate in its early stages. There unmet need for reliable method to monitor response treatment and assist surveillance. Circulating tumor DNA (ctDNA) testing shown great promise other solid tumors monitoring disease progression detecting relapse real time. This study aimed determine the feasibility use of personalized tumor-informed ctDNA SCCA.We analyzed real-world data from 251 patients...
PURPOSE Mucinous neoplasms of the gastrointestinal tract are characterized by a propensity for metastasis to peritoneum, resulting in peritoneal mucinous carcinomatosis (PMC). A subset these tumors, most often originating appendix, harbor mutations GNAS oncogene. While natural history -mutant PMC varies, patient outcomes generally poor, as is response cytotoxic chemotherapy. The purpose this study was evaluate clinical efficacy single-agent palbociclib, cyclin-dependent kinase (CDK)4/6...
4053 Background: Circulating tumor DNA (ctDNA) is a form of cell free that can be used to detect and measure cancer molecular residual disease (MRD) before after systemic therapy. There are no data pertaining the assessment MRD in patients with solid tumors treated chimeric antigen receptor T-cell (CAR-T) Here, we evaluated tumor-informed ctDNA assay setting gastric pancreatic malignancies claudin18.2 (CT041)-targeted CAR-T therapy (NCT04404595). Methods: A single-center review between...
Abstract: Genitourinary (GU) cancers are a group of epithelial malignancies associated with the organs involved in excretion urine. Renal cell, urothelial, and prostatic carcinoma overwhelming subtypes diagnosed by oncologists. Each these was traditionally treated surgically when local non-invasive. When carcinomas spread, invade, or metastasize, surgical control lacks efficacy. Chemotherapeutic regimens have been implemented for decades increased overall survival but many patients progress....